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Frances M. Walocko1, Benjamin Y. Scheier2, Paul W. Harms3,4, Leslie A. Fecher2 and Christopher D. Lao2*Erratum
Following publication of this article [1], it was noticed
that the Clinical Trial Number in the last paragraph of
the conclusions section was incorrectly listed as
NCT02155647. The correct Clinical Trials Number is
NCT02488759.
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